Methods for mitigating calcification and improving durability in glutaraldehyde-fixed bioprostheses and articles manufactured by such methods

• US 5,782,931 A
• Filed: 07/30/1996
• Issued: 07/21/1998
• Est. Priority Date: 07/30/1996
• Status: Expired due to Term

• Current Assignee: Edwards Lifesciences Corporation
• Original Assignee: Baxter International Inc.
• Inventors: Yang, Jun, Shen, Shih-Hwa
• Primary Examiner(s): DIAMOND, ALAN D
• Application Number:
  US08/688,352
• Time in Patent Office: 721 Days
• Field of Search: 8/94.11, 623/1, 623/2, 623/11, 623/12, 623/13, 623/14, 623/15
• US Class Current: 8/94.11
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: Y10S 623/916 Blood vessel
• CPC Class Codes: Y10S 623/918 Heart
• CPC Class Codes: Y10S 623/92 Method or apparatus for preparing or treating prosthetic
• CPC Class Codes: Y10S 623/921 Blood vessel

Abstract

Methods for treating glutaraldehyde-fixed collagenous tissues to mitigate their propensity for subsequent calcification and to improve durability. Collagenous tissues which have been harvested and cross-linked by glutaraldehyde are exposed to a carboxyl activating agent to convert the free carboxyl (COOH) groups of the collagen molecules to activated carboxyl moieties (e.g., o-acylisourea). Thereafter, the collagenous tissue is exposed to a compound capable of reacting with the activated carboxyl moieties (e.g., o-acylisourea) to form non-carboxyl side groups. Monofunctional and multi-functional amines are examples of compounds which may be utilized to react with the activated carboxyl moieties to form such non-carboxyl side groups. Thereafter, the collagenous tissue is again exposed to glutaraldehyde. If the non-carboxyl side groups have functional amino groups (NH₂), such additional exposure to glutaraldehyde will result in additional glutaraldehyde cross-linking of the collagen molecules and resultant improvement of durability.

Claims

1. A method for preparing a glutaraldehyde-fixed collagenous bioprosthesis having mitigated propensity for calcification, said method comprising the steps of:

a) providing a collagen-containing tissue;

b) contacting said tissue with glutaraldehyde to form a glutaraldehyde cross-linked tissue;

c) rising the tissue to remove residual glutaraldehyde such that the tissue is free of exogenous compounds which would deter the subsequent formation of activated carboxyl moieties on the tissue;

d) contacting the glutaraldehyde cross-linked tissue with a carboxyl activator compound capable of converting at least some of the carboxyl groups present on the collagen molecules of the tissue to activated carboxyl moieties capable of reacting with amino groups;

e) contacting the tissue from step d) with a compound that will react with the activated carboxyl moieties to form noncarboxyl side groups on the collagen molecules; and

, thereafter;

f) again contacting said tissue with glutaraldehyde.

2. The method of claim 1 wherein the collagenous tissue provided in step a is selected from the group consisting of:

heart valves;

segments of blood vessel;

segments of aortic root having an aortic valve positioned therewithin;

pericardium;

ligaments;

tendons; and

, skin.

3. The method of claim 1 wherein said tissue is of porcine origin.

4. The method of claim 1 wherein said tissue is of bovine origin.

5. The method of claim 1 wherein the compound contacted with the tissue in step e is a carboxyl-free monoamine.

6. The method of claim 5 wherein the carboxyl-free monoamine is aliphatic.

7. The method of claim 6 wherein the carboxyl-free aliphatic monoamine is propyl amine.

8. The method of claim 1 wherein the amine compound contacted with the tissue in step e is a carboxyl-free diamine.

9. The method of claim 8 wherein the carboxyl-free diamine compound is aliphatic.

10. The method of claim 9 wherein the carboxyl-free, aliphatic diamine compound is ethylene diamine.

11. The method of claim 1 wherein the compound used in step e contains at least two functional amino groups such that at least one functional amino group will remain on the amide-bound groups formed on the collagen molecules in step e, and wherein:

the subsequent contacting of the tissue with glutaraldehyde in step results in the formation of additional glutaraldehyde cross-linkages between the free amino groups which remain on the amide-bound groups of the collagen molecules within the tissue.

12. The method of claim 1 wherein the carboxyl activating compound used in step d is a carbodiimide.

13. The method of claim 12 wherein said carbodiimide is selected from the group consisting of:

1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC);

dihexylcarbodiimide (DCC); and

,

1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide iodide (EAC).

14. A method for treating a glutaraldehyde-fixed collagenous bioprosthesis to decrease its propensity for subsequent calcification, said method comprising the steps of:

a) providing a collagenous bioprosthesis which has been cross-linked with glutaraldehyde and is free of exogenous compounds which would deter the subsequent formation of activated carboxyl moieties on the tissue;

b) contacting at least some of the carboxyl groups present on collagen molecules of the cross-linked bioprosthesis with a carboxyl activating agent to convert at least some of the carboxyl groups into activated carboxyl moieties; and

,

c) their contacting a carboxyl-free compound with said activated carboxyl moieties to form carboxyl-free side groups on the collagen molecules of the bioprosthesis.

15. The method of claim 14 wherein the carboxyl activating compound is a carbodiimide.

16. The method of claim 15 wherein the carbodiimide is selected from the group consisting of:

1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC);

dihexylcarbodiimide (DCC); and

,

1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide iodide (EAC).

17. The method of claim 14 wherein the carboxyl-free compound used in step c is selected from the group consisting of:

amines;

monofunctional amines;

multifunctional amines;

aliphatic monofunctional amines;

aliphatic multifunctional amines;

diamines having terminal amino groups;

propyl amine; and

,

ethylene diamine.

18. The method of claim 14 further comprising the step of:

d) further contacting the bioprosthesis with glutaraldehyde.

19. The method of claim 18 wherein the carboxyl-free compound used in step c is an amine which has at least two functional amino groups such that one functional amino group reacts with the activated carboxyl moiety to form an amide linkage therewith and at least one other functional amino group will remain available for subsequent reaction with glutaraldehyde, and wherein the further exposure to glutaraldehyde in step d forms additional cross linkages between functional amino groups which remain in the carboxyl free side groups of the collagen molecules.

20. A method for preparing a glutaraldehyde-fixed collagenous tissue, said method comprising the steps of:

a) providing a collagen-containing tissue;

b) contacting said tissue with glutaraldehyde to form glutaraldehyde cross-linkages between collagen molecules within the tissue;

c) contacting the glutaraldehyde cross-linked tissue with a carboxyl activator compound capable of converting at least some of the carboxyl groups present on the collagen molecules of the tissue to activated carboxyl moieties capable of reacting with amino groups;

d) contacting the tissue with a carboxyl-free monoamine that will react with the activated carboxyl moieties to form noncarboxyl side groups on the collagen molecules; and

, thereafter;

e) again contacting said tissue with glutaraldehyde.

21. The method of claim 20 wherein the collagenous tissue provided in step a is selected from the group consisting of:

heart valves;

segments of blood vessel;

segments of aortic root having an aortic valve positioned therewithin;

pericardium;

ligaments;

tendons; and

,

skin.

22. The method of claim 20 wherein said tissue is of porcine origin.

23. The method of claim 20 wherein said tissue is of bovine origin.

24. The method of claim 20 wherein the carboxyl-free monoamine is aliphatic.

25. The method of claim 24 wherein the carboxyl-free aliphatic monoamine is propyl amine.

26. The method of claim 20 wherein the carboxyl activating compound used in step c is a carbodiimide.

27. The method of claim 26 wherein said carbodiimide is selected from the group consisting of:

1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC);

dihexylcarbodiimide (DCC); and

,

1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide iodide (EAC).

28. A method for treating a glutaraldehyde-fixed collagenous tissue to decrease its propensity for subsequent calcification, said method comprising the steps of:

a) providing a collagenous tissue which has been cross-linked with glutaraldehyde;

b) reacting at least some of the carboxyl groups present on collagen molecules of the tissue with a carboxyl activating agent to convert at least some of the carboxyl groups into activated carboxyl moieties; and

,

c) reacting a carboxyl-free monoamine with said activated carboxyl moieties to form carboxyl-free side groups on the collagen molecules of the tissue.

29. The method of claim 28 wherein the carboxyl activating compound is a carbodiimide.

30. The method of claim 29 wherein the carbodiimide is selected from the group consisting of:

1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC);

dihexylcarbodiimide (DCC); and

,

1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide iodide (EAC).

31. The method of claim 28 further comprising the step of:

d) further contacting the tissue with glutaraldehyde.

32. The method of claim 28 wherein the carboxyl-free monoamine is aliphatic.

33. The method of claim 28 wherein the carboxyl-free aliphatic monoamine is propyl amine.